Logo

GSK Tests out Ambit s Profiling Technology

Mar 04, 2003

NEW YORK, March 4 - GlaxoSmithKline is evaluating Ambit Biosciences' screening technology to characterize small molecule kinase inhibitors, Ambit said today.

 

Since January, Ambit has been studying interactions between GSK's kinase inhibitors and proteins using its phage display-based screening approach.

 

Ambit Biosciences is based in San Diego.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.